Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology

Rodolfo Savica; Melissa E. Murray; Xuan Mai Persson; Kejal Kantarci; Joseph E. Parisi; Dennis W. Dickson; Ronald C. Petersen; Tanis J. Ferman; Bradley F. Boeve; Michelle M. Mielke

doi:10.1016/j.dadm.2016.02.005

Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology

Rodolfo Savica, Melissa E. Murray, Xuan Mai Persson, Kejal Kantarci, Joseph E. Parisi, Dennis W. Dickson, Ronald C. Petersen, Tanis J. Ferman, Bradley F. Boeve, Michelle M. Mielke

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Introduction: The clinical and pathological phenotypes of Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) often overlap. We examined whether plasma lipids differed among individuals with autopsy-confirmed Lewy Body pathology or AD pathology. Methods: We identified four groups with available plasma 2 years before death: high (n = 12) and intermediate-likelihood DLB (n = 14) based on the third report of the DLB consortium; dementia with Alzheimer's pathology (AD; n = 18); and cognitively normal with normal aging pathology (n = 21). Lipids were measured using ESI/MS/MS. Results: There were overall group differences in plasma ceramides C16:0, C18:1, C20:0, and C24:1 and monohexosylceramides C18:1 and C24:1. These lipids did not differ between the high-likelihood DLB and AD groups, but both groups had higher levels than normals. Plasma fatty acid levels did not differ by group. Discussion: Plasma ceramides and monohexosylceramides are elevated in people with dementia with either high-likelihood DLB or AD pathology.

Original language	English (US)
Pages (from-to)	43-50
Number of pages	8
Journal	Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume	3
DOIs	https://doi.org/10.1016/j.dadm.2016.02.005
State	Published - 2016
Externally published	Yes

Keywords

Alzheimer's disease
Autopsy
Ceramide
Lewy body
Lipids

ASJC Scopus subject areas

Psychiatry and Mental health
Clinical Neurology

Access to Document

10.1016/j.dadm.2016.02.005

Cite this

@article{82c5e5779c5840f9a39f74a5b6696738,

title = "Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology",

abstract = "Introduction: The clinical and pathological phenotypes of Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) often overlap. We examined whether plasma lipids differed among individuals with autopsy-confirmed Lewy Body pathology or AD pathology. Methods: We identified four groups with available plasma 2 years before death: high (n = 12) and intermediate-likelihood DLB (n = 14) based on the third report of the DLB consortium; dementia with Alzheimer's pathology (AD; n = 18); and cognitively normal with normal aging pathology (n = 21). Lipids were measured using ESI/MS/MS. Results: There were overall group differences in plasma ceramides C16:0, C18:1, C20:0, and C24:1 and monohexosylceramides C18:1 and C24:1. These lipids did not differ between the high-likelihood DLB and AD groups, but both groups had higher levels than normals. Plasma fatty acid levels did not differ by group. Discussion: Plasma ceramides and monohexosylceramides are elevated in people with dementia with either high-likelihood DLB or AD pathology.",

keywords = "Alzheimer's disease, Autopsy, Ceramide, Lewy body, Lipids",

author = "Rodolfo Savica and Murray, {Melissa E.} and Persson, {Xuan Mai} and Kejal Kantarci and Parisi, {Joseph E.} and Dickson, {Dennis W.} and Petersen, {Ronald C.} and Ferman, {Tanis J.} and Boeve, {Bradley F.} and Mielke, {Michelle M.}",

year = "2016",

doi = "10.1016/j.dadm.2016.02.005",

language = "English (US)",

volume = "3",

pages = "43--50",

journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",

issn = "2352-8729",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology

AU - Savica, Rodolfo

AU - Murray, Melissa E.

AU - Persson, Xuan Mai

AU - Kantarci, Kejal

AU - Parisi, Joseph E.

AU - Dickson, Dennis W.

AU - Petersen, Ronald C.

AU - Ferman, Tanis J.

AU - Boeve, Bradley F.

AU - Mielke, Michelle M.

PY - 2016

Y1 - 2016

N2 - Introduction: The clinical and pathological phenotypes of Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) often overlap. We examined whether plasma lipids differed among individuals with autopsy-confirmed Lewy Body pathology or AD pathology. Methods: We identified four groups with available plasma 2 years before death: high (n = 12) and intermediate-likelihood DLB (n = 14) based on the third report of the DLB consortium; dementia with Alzheimer's pathology (AD; n = 18); and cognitively normal with normal aging pathology (n = 21). Lipids were measured using ESI/MS/MS. Results: There were overall group differences in plasma ceramides C16:0, C18:1, C20:0, and C24:1 and monohexosylceramides C18:1 and C24:1. These lipids did not differ between the high-likelihood DLB and AD groups, but both groups had higher levels than normals. Plasma fatty acid levels did not differ by group. Discussion: Plasma ceramides and monohexosylceramides are elevated in people with dementia with either high-likelihood DLB or AD pathology.

AB - Introduction: The clinical and pathological phenotypes of Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) often overlap. We examined whether plasma lipids differed among individuals with autopsy-confirmed Lewy Body pathology or AD pathology. Methods: We identified four groups with available plasma 2 years before death: high (n = 12) and intermediate-likelihood DLB (n = 14) based on the third report of the DLB consortium; dementia with Alzheimer's pathology (AD; n = 18); and cognitively normal with normal aging pathology (n = 21). Lipids were measured using ESI/MS/MS. Results: There were overall group differences in plasma ceramides C16:0, C18:1, C20:0, and C24:1 and monohexosylceramides C18:1 and C24:1. These lipids did not differ between the high-likelihood DLB and AD groups, but both groups had higher levels than normals. Plasma fatty acid levels did not differ by group. Discussion: Plasma ceramides and monohexosylceramides are elevated in people with dementia with either high-likelihood DLB or AD pathology.

KW - Alzheimer's disease

KW - Autopsy

KW - Ceramide

KW - Lewy body

KW - Lipids

UR - http://www.scopus.com/inward/record.url?scp=84961626573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961626573&partnerID=8YFLogxK

U2 - 10.1016/j.dadm.2016.02.005

DO - 10.1016/j.dadm.2016.02.005

M3 - Article

C2 - 27152320

AN - SCOPUS:84961626573

SN - 2352-8729

VL - 3

SP - 43

EP - 50

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

ER -

Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this